Quantitative assessment of IFN-γ release following stimulation with SARS-CoV-2-derived peptides revealed no significant differences between CLL patients and HCs (Figure 2A,B). The gene discussed is IFNG; the disease is B-cell chronic lymphocytic leukemia.